Phillips-Medisize, a subsidiary of Molex, has announced a collaboration with GlucoModicum to develop an innovative continuous glucose monitor (CGM).
This partnership aims to create and eventually bring to market a proprietary, non-invasive wearable CGM device with the goal of addressing current technological and patient-care challenges in continuous glucose monitoring.
Phillips-Medisize specialises in the development of medical devices, including drug delivery systems, in vitro diagnostic tools, and medtech devices. GlucoModicum, based in Finland, utilises magnetohydrodynamic (MHD) technology to efficiently extract glucose samples in a non-invasive manner. This cutting-edge technology applies a minimal amount of energy directly to interstitial fluid, facilitating the movement of glucose to the skin's surface.
The resulting device, named "Talisman," is designed to be adhered to a patient's arm. It seamlessly integrates MHD technology, highly sensitive biosensors, and advanced algorithms, all while being capable of connecting to a smartphone app for convenient glucose level monitoring. It's important to note that this device is still in the investigational stage.
Click here to read the original news story.